In fact, validation of the molecular classification in high-grade and/or high-risk endometrial carcinomas shows that the POLE-mut tumors have an excellent prognosis, while the p53-abn neoplasms have a poor prognosis. This evidence concerns the gene POLE and endometrial carcinoma.